A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

Inclusion Criteria:

- Is receiving prophylaxis for or has a confirmed or suspected infection with
gram-positive bacteria and receiving concurrent antibiotic treatment with gram
-positive antibacterial activity.

- Is at least 1 kg in weight; and weighs within >5th percentile and <95th percentile
based on age.

- Is in stable condition as determined from medical history, physical examination,
electrocardiogram (ECG), vital signs, and clinical laboratory evaluations.

- Has no clinically significant ECG abnormalities.

- Has sufficient vascular access to receive trial drug, and allow for required blood
draws.

- Is able to receive food and medication by mouth, for those dosed with oral suspension.

Exclusion Criteria:

- Has a history of seizures, other than febrile seizures, clinically significant cardiac
arrhythmia or condition, cystic fibrosis, moderate or severe renal impairment, or any
physical condition that could interfere with the interpretation of the study results,
as determined by the Investigator.

- Has used rifampin within 14 days prior to dosing.

- Has used or will be using ranitidine, cimetidine or antacids (for those taking oral
suspension dose) at any time from 24 hours prior to dosing through 24 hours after
dosing.

- Has a recent (3-month) history or current infection with viral hepatitis or other
significant hepatic disease.

- Has a history of drug allergy or hypersensitivity to oxazolidinones.

- Has had significant blood loss.

- Need for oral administration of topotecan, rosuvastatin, irinotecan, or methotrexate
during administration of oral study drug.

- Used monoamine oxidase inhibitors (MAOIs) or serotonergic agents including tricyclic
antidepressants, selective serotonin reuptake inhibitors (SSRIs), and serotonin
5-hydroxytryptamine receptor agonists (triptans), meperidine, or buspirone within 14
days prior to study, or planned use while on study.

- Has received another investigational product within the 30 days prior to enrollment.